HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM:NTEC) announced that two posters were presented regarding preclinical data for GlycoPEGylated recombinant Factor VIIa at the American Society of Hematology 49th Annual Meeting and Exposition in Altanta, Georgia. GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose.
